SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (463)2/3/2009 4:51:13 PM
From: ghmm  Read Replies (1) of 508
 
Appreciate the feedback.

I don’t have a stats background and have been looking at the Repeated Measures Analysis. Seems like a good analysis that minimizes bias. Would it bother you that this is done retrospectively?

One thing about 6MWT again going to baseline level (slide 12), the values were significantly lower in Cap-1 then Cap-2 (almost 10%) while I can’t give you specifics off the top of my head in general in PAH trials the lower the baseline the greater the magnitude of improvement.

If I recall correctly though companies have argued against 6MWT FDA had liked that end point. Believe several IPF trials in past had that as end-point and sildenafil does in current IPF trial.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News